The Power of Clinical Trial Tokenisation

This Financial Times Digital Dialogue, held in partnership with ICON, brought together pioneering early adopters of clinical trial tokenisation and other industry experts to discuss the potentially transformative role tokenisation, and the ability it brings to share patient-level data securely across the healthcare ecosystem,  can play in enhancing patient safety and improving drug development.

Trust

Will patients place trust in tokenisation as a research tool? The importance of patient education and consent. How do you create a level of comfort for the patient and manage the burden for sites and investigators?

Clincal Trial Tokenisation

How does tokenisation work? Understanding the journey towards tokenisation in clinical trials - key steps and considerations; What kinds of trials are most suited to tokenisation and data linkage (use case, trial size)? When should tokenisation take place- at the beginning, during or at end of the trial?

Future scoping

What are the potential future use cases of tokenisation? How might the data ecosystem develop? The impact of patients owning data and the monetisation of patient data 

Understand

The big picture, not just the individual strands of the business you work in

Discover

New approaches and strategies to help win market share

FT Live Digital Dialogues - fully digital one hour event experiences delivering maximum engagement. Live webinars provide unique opportunities to engage global senior audiences. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days. Join the conversation.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice